Do primate action plans work?

John Oates authored the first primate conservation Action Plan in 1986, which assessed the status of and proposed conservation actions for all mainland African primate species. A revised version of the continent-wide plan was published in 1996, but since then, action plans have generally evolved into prioritizing actions for specific species, often within defined landscapes. We will review and evaluate the content and success of conservation action plans for the nine currently recognized taxa of chimpanzees and gorillas in Africa. Since 2003, six detailed action plans and one population viability analysis have been published, covering priority actions and landscapes for seven of the nine great ape taxa in Africa. Two further action plans (for gorillas and chimpanzees in Eastern DRC and for bonobos) are in the final stages of review and may also be included in the analysis. Assessments for western chimpanzees, Cross River gorillas, western lowland gorillas and central chimpanzees have been peer reviewed, and we will consider their recommendations and the challenges of quantitatively evaluating the success of primate conservation action plans

Quantifying the scale and socioeconomic drivers of bird hunting in Central African forest communities

Global biodiversity is threatened by unsustainable exploitation for subsistence and commerce, and tropical forests are facing a hunting crisis. In Central African forests, hunting pressure has been quantified by monitoring changes in the abundance of affected species and by studying wild meat consumption, trade and hunter behaviour. However, a proportion of offtake is also discarded as bycatch or consumed by hunters when working, which can be overlooked by these methods. For example, remains of hornbills and raptors are found regularly in hunting camps but relatively few birds are consumed in households or traded in markets. Hornbill and raptor populations are sensitive to small increases in mortality because of their low intrinsic population growth rates, however, the scale and socioeconomic drivers of the cryptic hunting pressure affecting these species have not been quantified. We used direct and indirect questioning and mixed-effects models to quantify the socioeconomic predictors, scale and seasonality of illegal bird hunting and consumption in Littoral Region, Cameroon. We predicted that younger, unemployed men with low educational attainment (i.e. hunters) would consume birds more often than other demographics, and that relative offtake would be higher than expected based on results from village and market-based studies. We found that birds were primarily hunted and consumed by unemployed men during the dry season but, in contrast to expectations, we found that hunting prevalence increased with educational attainment. Within unemployed men educated to primary level (240 of 675 respondents in 19 villages), we estimated an average of 29 hornbills and eight raptors (compared with 19 pangolins) were consumed per month during the study period (Feb–Jun 2015) in a catchment of c.1135 km2. We conclude that large forest birds face greater hunting pressure than previously recognised, and birds are a regular source of protein for men during unemployment. Offtake levels may be unsustainable for some raptors and hornbills based on life history traits but in the absence of sufficient baseline ecological and population data we recommend that a social-ecological modeling approach is used in future to quantify hunting sustainability

Chimpanzee population structure in Cameroon and Nigeria is associated with habitat variation that may be lost under climate change

Background: The Nigeria-Cameroon chimpanzee (Pan troglodytes ellioti) is found in the Gulf of Guinea biodiversity hotspot located in western equatorial Africa. This subspecies is threatened by habitat fragmentation due to logging and agricultural development, hunting for the bushmeat trade, and possibly climate change. Although P. t. ellioti appears to be geographically separated from the neighboring central chimpanzee (P. t. troglodytes) by the Sanaga River, recent population genetics studies of chimpanzees from across this region suggest that additional factors may also be important in their separation. The main aims of this study were: 1) to model the distribution of suitable habitat for P. t. ellioti across Cameroon and Nigeria, and P. t. troglodytes in southern Cameroon, 2) to determine which environmental factors best predict their optimal habitats, and 3) to compare modeled niches and test for their levels of divergence from one another. A final aim of this study was to examine the ways that climate change might impact suitable chimpanzee habitat across the region under various scenarios. Results: Ecological niche models (ENMs) were created using the software package Maxent for the three populations of chimpanzees that have been inferred to exist in Cameroon and eastern Nigeria: (i) P. t. troglodytes in southern Cameroon, (ii) P. t. ellioti in northwestern Cameroon, and (iii) P. t. ellioti in central Cameroon. ENMs for each population were compared using the niche comparison test in ENMtools, which revealed complete niche divergence with very little geographic overlap of suitable habitat between populations. Conclusions: These findings suggest that a positive relationship may exist between environmental variation and the partitioning of genetic variation found in chimpanzees across this region. ENMs for each population were also projected under three different climate change scenarios for years 2020, 2050, and 2080. Suitable habitat of P. t. ellioti in northwest Cameroon / eastern Nigeria is expected to remain largely unchanged through 2080 in all considered scenarios. In contrast, P. t. ellioti in central Cameroon, which represents half of the population of this subspecies, is expected to experience drastic reductions in its ecotone habitat over the coming century

Revised Regional Action Plan for the Conservation of the Cross River Gorilla (Gorilla gorilla diehli) 2014–2019

This plan outlines measures that should ensure that Cross River gorilla numbers are able to increase at key core sites, allowing them to extend into areas where they have been absent for many years

Regional Action Plan for the Conservation of the Nigeria–Cameroon Chimpanzee (Pan troglodytes ellioti)

First paragraph: This document represents the consensus of views from forestry and wildlife conservation agencies in Nigeria and Cameroon, local and international nongovernmental conservation organizations, and university-based researchers who met at a series of workshops in Cameroon and Nigeria to formulate a set of actions that, if implemented, will increase the longterm survival prospects of the Nigeria-Cameroon chimpanzee, Pan troglodytes ellioti. The Nigeria-Cameroon chimpanzee is the most endangered of all currently recognized chimpanzee subspecies, with a total remaining population of between 3,500 and 9,000 living in forested habitat to the north of the Sanaga River in Cameroon, the eastern edge of Nigeria, and in forest fragments in the Niger Delta and southwestern Nigeri

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention